Exenatide Therapy and the Risk of Pancreatitis and Pancreatic Cancer in a Privately Insured Population
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Postmarketing reports have linked exenatide use with acute pancreatitis and pancreatic cancer, but a definitive relationship has yet to be established. SUBJECTS AND METHODS: We conducted a retrospective cohort analysis of patients with type 2 diabetes with employer-provided health insurance from 2007 to 2009. Multivariate models estimated the association between exenatide use and acute pancreatitis and pancreatic cancer. We required at least 1 year of exenatide exposure in the pancreatic cancer analysis. Sensitivity analyses were conducted that quasirandomized exenatide use based on patient out-of-pocket costs. RESULTS: Among 268,561 patients included in the acute pancreatitis analysis, only 2.6% used exenatide. Hospitalization for acute pancreatitis was rare (0.247% of patients). In unadjusted and adjusted analyses, patients who did not use exenatide were more likely to be hospitalized for acute pancreatitis (0.249% vs. 0.196% in unadjusted analysis), but the difference was not statistically significant in either analysis (P = 0.22 and P = 0.70, respectively). Among 209,306 patients in the pancreatic cancer analysis, 0.070% were diagnosed with pancreatic cancer, and 0.88% had at least 1 year of continuous exenatide exposure prior to the diagnosis. Those with exenatide exposure had higher rates of pancreatic cancer compared with those without (0.081% vs. 0.070% in unadjusted analysis). In both unadjusted and adjusted analyses, the difference was not statistically significant (P = 0.80 and P = 0.46, respectively). In sensitivity analyses, results were similar. CONCLUSIONS: We found no association between exenatide use and either hospitalization for acute pancreatitis or pancreatic cancer in a large sample of privately insured U.S. patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies
Elashoff, M., Matveyenko, A. V., Gier, B., Elashoff, R., & Butler, P. C. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.02.018 · Cited by 944 · cited 4×
“By examining the most recent administrative data available (2009), our analysis examines a time period that is equivalent to the only published analysis that broadly examines exenatide’s pancreatic cancer risk.(10) Furthermore, for patients who took 365 days or more of exenatide prior to the year of incident cancer di…”
BackgroundMethodResultInfluentialExenatide (Exendin-4)–Induced Pancreatitis
Denker, P. S., & Dimarco, P. E. (2006) · Diabetes Care · doi:10.2337/diacare.29.02.06.dc05-2043 · Cited by 140 · cited 1×
“However, postmarketing reports of acute pancreatitis, including severe forms such as hemorrhagic or necrotizing pancreatitis, developing in patients taking exenatide were submitted to the Food and Drug Administration (FDA)(1,2) and have been published in the literature.(3,4) Although these reports do not prove a causa…”
BackgroundExenatide-Induced Acute Pancreatitis
Ayoub, W. A., Kumar, A. A., Naguib, H. S., & Taylor, H. C. (2010) · Endocrine Practice · doi:10.4158/ep09104.crr · Cited by 58 · cited 1×
“However, postmarketing reports of acute pancreatitis, including severe forms such as hemorrhagic or necrotizing pancreatitis, developing in patients taking exenatide were submitted to the Food and Drug Administration (FDA)(1,2) and have been published in the literature.(3,4) Although these reports do not prove a causa…”
Background
Cited by
Filippatos, T. D., Panagiotopoulou, T. V., & Elisaf, M. S. (2014) · The Review of Diabetic Studies · Cited by 560
Li, L., Shen, J., Bala, M. M., Busse, J. W., Ebrahim, S., Vandvik, P. O., Rios, L. P., Malaga, G., Wong, E., Sohani, Z., et al. (2014) · BMJ · doi:10.1136/bmj.g2366 · Cited by 254
Monami, M., Nreu, B., Scatena, A., Cresci, B., Andreozzi, F., Sesti, G., & Mannucci, E. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12926 · Cited by 243
Cao, C., Yang, S., & Zhou, Z. (2020) · Endocrine · doi:10.1007/s12020-020-02223-6 · Cited by 124
Incretin based drugs and the risk of pancreatic cancer: international multicentre cohort study
Azoulay, L., Filion, K. B., Platt, R. W., Dahl, M., Dormuth, C. R., Clemens, K. K., Durand, M., Juurlink, D. N., Targownik, L. E., Turin, T. C., et al. (2016) · BMJ · doi:10.1136/bmj.i581 · Cited by 120
Metadata
- Authors
- Romley, J. A., Goldman, D. P., Solomon, M., McFadden, D., & Peters, A. L.
- Venue
- Diabetes Technology & Therapeutics
- Publisher
- SAGE Publications
- Published
- 2012-10
- Volume
- 14
- Issue
- 10
- Pages
- 904-911
- ISSN
- 1520-9156 (ISSN-L)
- 1557-8593
- OpenAlex
- W2066987382
- Cited by
- 85
- References
- 3
- FWCI
- 8.97
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Exenatide Therapy and the Risk of Pancreatitis and Pancreatic Cancer in a Privately Insured Population. https://app.cochat.ai/papers/10.1089/dia.2012.0075
- The paper
- Romley, J. A., Goldman, D. P., Solomon, M., McFadden, D., & Peters, A. L. (2012). Exenatide Therapy and the Risk of Pancreatitis and Pancreatic Cancer in a Privately Insured Population. Diabetes Technology & Therapeutics. https://doi.org/10.1089/dia.2012.0075
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.